It highlights a potential new therapeutic avenue for patients with obesity-associated asthma. In a real-world retrospective cohort study, Patel and colleagues at Drexel University College of Medicine assessed patients from the TriNetX global collaborative network without diabetes but with asthma belonging to one of three weight classes overweight (BMI 25 kg/m 2 -29.99 kg/m 2 ), obese (BMI 30 kg/m 2 -40 kg/m 2 ) or morbidly obese (BMI at least 40 kg/m 2 ) to determine the impact of GLP-1 receptor agonist treatment on the risk for asthma exacerbation
It's a precursor to cysteine and taurine, both critical for mitochondrial function and bile acid conjugation
Practical Strategies and When to Pause or Adjust Treatment If you experience significant fatigue on GLP-1, evidence-backed strategies include optimizing hydration (fluid losses increase with rapid weight loss), ensuring adequate protein intake (minimum 1.2 g/kg to preserve muscle and energy), and checking biomarkers at 46 weeks to identify correctable deficiencies
The metabolites of IGF-1 LR3 had a slightly longer half-life and were detectable for up to 16 hours after the injection
Why the heart and liver benefit, even without direct targets Habegger says one of the most striking findings from large clinical trials is that GLP-1 drugs reduce the risk of heart attacks, strokes and cardiovascular death
Now the second group is these, kind of, disruptive tech investors